These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 10601802)

  • 1. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
    Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
    Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with long-term treatment with albumin-supplemented botulinum toxin type A.
    Mohammadi B; Kollewe K; Wegener M; Bigalke H; Dengler R
    J Neural Transm (Vienna); 2009 Apr; 116(4):437-41. PubMed ID: 19319477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
    Yabiku MM; Sartori Jde F; Sarraff EP; Osaki TH; Hossaka SK; Pereira CI; Freitas Wd; Osaki MH; Cariello AJ
    Arq Bras Oftalmol; 2011; 74(6):414-6. PubMed ID: 22331113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.
    Laubis-Herrmann U; Fries K; Topka H
    Eur Neurol; 2002; 47(4):214-21. PubMed ID: 12037435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
    Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
    Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Botulinum toxin therapy for focal dystonia].
    Hahn K; Niklai E; Garzuly F; Szupera Z
    Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
    Kongsengdao S; Kritalukkul S
    J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
    Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
    Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
    Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
    Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of long term treatment of essential blepharospasm and facial hemispasm with botulinum toxin A].
    Ziak P
    Cesk Slov Oftalmol; 2004 Jan; 60(1):37-44. PubMed ID: 15011305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Alleviating Maneuvers for Periocular Facial Dystonias.
    Kilduff CL; Casswell EJ; Salam T; Hersh D; Ortiz-Perez S; Ezra D
    JAMA Ophthalmol; 2016 Nov; 134(11):1247-1252. PubMed ID: 27606483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
    Li XH; Lin SC; Hu YF; Liu LY; Liu JB; Hong YC
    Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Botulinum toxin injections under electromyographic guidance].
    Bogucki A
    Neurol Neurochir Pol; 1998; 32 Suppl 1():85-93. PubMed ID: 9608557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
    Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
    Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
    Jost WH; Kohl A
    J Neurol; 2001 Apr; 248 Suppl 1():21-4. PubMed ID: 11357234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
    Thussu A; Barman CR; Prabhakar S
    Neurol India; 1999 Sep; 47(3):206-9. PubMed ID: 10514580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.